Loading...
Hot flashes associated with natural, surgical, or chemotherapy-induced menopause can substantially disrupt sleep and quality of life (QOL) for women with or at high risk for breast cancer. Serotonin-norepinephrine or selective serotonin reuptake inhibitors (SNRIs or SSRIs) are commonly prescribed for women with hot flashes but are not universally effective. Investigators theorized that augmenting such therapies with a sleep agent might improve both sleep and QOL. In a manufacturer-supported trial, 53 white women (mean age, 51; mean body-mass index, 28.7 kg/m2) who had or were at high risk for breast cancer and who experienced ≥3 nightly hot-flash–related awakenings 3 times weekly for 1 month were randomized to receive the hypnotic agent zol…